PDCD1 and melanoma: Overall, PD1/PDL1 blockade only elicited cumulative response rates of 31% in patients with melanoma, 19% in patients with NSCLC, 25% in patients with renal cell carcinoma (RCC), and 13.3% in patients with head and neck cancers [47–50].